Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The University of Hong Kong
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female patients, from 18 to 65 years of age at Visit 1
Patients must achieve a level of understanding and expressive capacity sufficient to communicate adequately with the study coordinator and to participate in cognitive testing.
Patients must agree to cooperate with all tests and examinations required by the protocol. They must be willing to comply fully with treatment
Patient must understand the nature of the study and must sign an informed consent document.
Patients must be Cantonese speaking Han Chinese
Patients must be diagnosed, according to the SCID for DSM-IV, with schizophrenia, schizoaffective disorder or schizophreniform psychosis.
Patients must have good response to anti-psychotic treatment by achieving a rating of 2 or below in Clinical Global Impression Scale (CGI) Severity of illness; a rating of 4 or below in Improvement scale, and a rating of 3 or below in (conceptual disorganization, unusual thought content), a rating of 2 or below in (delusion, hallucinatory behavior) and a rating of 4 or below in (Suspiciousness) of Positive and Negative Syndrome Scale (PANSS) for at least 8 weeks
You may not be if
Female patients who are either pregnant or lactating.
Patients previously on clozapine should be excluded from the study
Significant medical illnesses including seizures.
DSM-IV substance (alcohol or other drugs) abuse or dependence within the past 3 months.
Judged clinically to be at serious suicidal risk.
Treatment with an injectable depot neuroleptic within less than one of the patient's dosing intervals between depot neuroleptic injections prior to study entry.
